Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_4
1
25%
Ph phase_3
1
25%
Ph phase_2
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(3)

Detailed Status

Completed3
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (33.3%)
Phase 31 (33.3%)
Phase 41 (33.3%)

Trials by Status

recruiting125%
completed375%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_3

Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)

NCT06952452
completedphase_2

Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration

NCT00764738
completed

Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema

NCT02979665
completedphase_4

VEGF Concentrations After Intravitreal Bevacizumab vs Ranibizumab as a Treatment for Type 1 ROP

NCT03148132

Clinical Trials (4)

Showing 4 of 4 trials
NCT06952452Phase 3

Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)

Recruiting
NCT00764738Phase 2

Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration

Completed
NCT02979665

Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema

Completed
NCT03148132Phase 4

VEGF Concentrations After Intravitreal Bevacizumab vs Ranibizumab as a Treatment for Type 1 ROP

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4